Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical Potential

被引：47

作者：

Galletti, Giuseppe ^{[1
,2
]}

Portella, Luigi ^{[1
,2
]}

Tagawa, Scott T. ^{[1
,2
]}

Kirby, Brian J. ^{[1
,2
,3
]}

Giannakakou, Paraskevi ^{[1
,2
]}

Nanus, David M. ^{[1
,2
]}

机构：

[1] Weill Cornell Med Coll, Div Hematol & Med Oncol, New York, NY 10021 USA

[2] Weill Cornell Med Coll, Weill Cornell Canc Ctr, New York, NY 10021 USA

[3] Cornell Univ, Sibley Sch Mech & Aerosp Engn, Ithaca, NY 14853 USA

来源：

MOLECULAR DIAGNOSIS & THERAPY | 2014年 / 18卷 / 04期

关键词：

MITOXANTRONE PLUS PREDNISONE; ANDROGEN RECEPTOR; PERIPHERAL-BLOOD; BREAST-CANCER; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; PREDICT SURVIVAL; END-POINTS; ANTIGEN; EXPRESSION;

D O I：

10.1007/s40291-014-0101-8

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Circulating tumor cells (CTCs) have emerged as a viable solution to the lack of tumor tissue availability for patients with a variety of solid tumors, including prostate cancer. Different approaches have been used to capture this tumor cell population and several of these techniques have been used to assess the potential role of CTCs as a biological marker to predict treatment efficacy and clinical outcome. CTCs are now considered a strong tool to understand the molecular characteristics of prostate cancer, and to be used and analyzed as a 'liquid biopsy' in the attempt to grasp the biological portrait of the disease in the individual patient.

引用

页码：389 / 402

页数：14

共 103 条

[81] Prostate cancer clinical trial end points: "RECIST"ing a step backwards [J].

Scher, HI ;

Morris, MJ ;

Kelly, WK ;

Schwartz, LH ;

Heller, G .

CLINICAL CANCER RESEARCH, 2005, 11 (14) :5223-5232

[82]

Scher HI, 2013, EUR CANC C

[83] Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy [J].

Scher, Howard I. ;

Fizazi, Karim ;

Saad, Fred ;

Taplin, Mary-Ellen ;

Sternberg, Cora N. ;

Miller, Kurt ;

de Wit, Ronald ;

Mulders, Peter ;

Chi, Kim N. ;

Shore, Neal D. ;

Armstrong, Andrew J. ;

Flaig, Thomas W. ;

Flechon, Aude ;

Mainwaring, Paul ;

Fleming, Mark ;

Hainsworth, John D. ;

Hirmand, Mohammad ;

Selby, Bryan ;

Seely, Lynn ;

de Bono, Johann S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (13) :1187-1197

[84] Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study [J].

Scher, Howard I. ;

Beer, Tomasz M. ;

Higano, Celestia S. ;

Anand, Aseem ;

Taplin, Mary-Ellen ;

Efstathiou, Eleni ;

Rathkopf, Dana ;

Shelkey, Julia ;

Yu, Evan Y. ;

Alumkal, Joshi ;

Hung, David ;

Hirmand, Mohammad ;

Seely, Lynn ;

Morris, Michael J. ;

Danila, Daniel C. ;

Humm, John ;

Larson, Steve ;

Fleisher, Martin ;

Sawyers, Charles L. .

LANCET, 2010, 375 (9724) :1437-1446

[85] Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data [J].

Scher, Howard I. ;

Jia, Xiaoyu ;

de Bono, Johann S. ;

Fleisher, Martin ;

Pienta, Kenneth J. ;

Raghavan, Derek ;

Heller, Glenn .

LANCET ONCOLOGY, 2009, 10 (03) :233-239

[86] Screening and Prostate-Cancer Mortality in a Randomized European Study [J].

Schroeder, Fritz H. ;

Hugosson, Jonas ;

Roobol, Monique J. ;

Tammela, Teuvo L. J. ;

Ciatto, Stefano ;

Nelen, Vera ;

Kwiatkowski, Maciej ;

Lujan, Marcos ;

Lilja, Hans ;

Zappa, Marco ;

Denis, Louis J. ;

Recker, Franz ;

Berenguer, Antonio ;

Maattanen, Liisa ;

Bangma, Chris H. ;

Aus, Gunnar ;

Villers, Arnauld ;

Rebillard, Xavier ;

van der Kwast, Theodorus ;

Blijenberg, Bert G. ;

Moss, Sue M. ;

de Koning, Harry J. ;

Auvinen, Anssi .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (13) :1320-1328

[87] Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer [J].

Shaffer, David R. ;

Leversha, Margaret A. ;

Danila, Daniel C. ;

Lin, Oscar ;

Gonzalez-Espinoza, Rita ;

Gu, Bin ;

Anand, Aseem ;

Smith, Katherine ;

Maslak, Peter ;

Doyle, Gerald V. ;

Terstappen, Leon W. M. M. ;

Lilja, Hans ;

Heller, Glenn ;

Fleisher, Martin ;

Scher, Howard I. .

CLINICAL CANCER RESEARCH, 2007, 13 (07) :2023-2029

[88] Whole Blood Stem Cell Reinfusion and Escalated Dose Melphalan in Castration-Resistant Prostate Cancer: A Phase 1 Study [J].

Shamash, Jonathan ;

Jacob, Jimmy ;

Agrawal, Samir ;

Powles, Thomas ;

Mutsvangwa, Katherine ;

Wilson, Peter ;

Stebbing, Justin .

CLINICAL CANCER RESEARCH, 2012, 18 (08) :2352-2359

[89] Cancer Statistics, 2012 [J].

Siegel, Rebecca ;

Naishadham, Deepa ;

Jemal, Ahmedin .

CA-A CANCER JOURNAL FOR CLINICIANS, 2012, 62 (01) :10-29

[90] Isolation of circulating tumor cells using a microvortex-generating herringbone-chip [J].

Stott, Shannon L. ;

Hsu, Chia-Hsien ;

Tsukrov, Dina I. ;

Yu, Min ;

Miyamoto, David T. ;

Waltman, Belinda A. ;

Rothenberg, S. Michael ;

Shah, Ajay M. ;

Smas, Malgorzata E. ;

Korir, George K. ;

Floyd, Frederick P., Jr. ;

Gilman, Anna J. ;

Lord, Jenna B. ;

Winokur, Daniel ;

Springer, Simeon ;

Irimia, Daniel ;

Nagrath, Sunitha ;

Sequist, Lecia V. ;

Lee, Richard J. ;

Isselbacher, Kurt J. ;

Maheswaran, Shyamala ;

Haber, Daniel A. ;

Toner, Mehmet .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (43) :18392-18397

← 2 3 4 5 6 7 8 9 10 11 →